Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Active:	Yes
Cancer Type:	Leukemia	NCT ID:	NCT03850574
Trial Phases:	Phase I Phase II	Protocol IDs:	HM-FLTI-101 (primary) NCI-2019-06837
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Aptose Biosciences
NCI Full Details:	http://clinicaltrials.gov/show/NCT03850574

Summary

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety,
Tolerability, Pharmacokinetics, and Pharmacodynamics of Tuspetinib (HM43239) in Patients with
Relapsed or Refractory Acute Myeloid Leukemia (AML)

Objectives

This is a Phase 1/2, open-label, multi-center study to assess the efficacy, safety,
tolerability, pharmacokinetics, including recommended phase 2 dose (RP2D) of tuspetinib
(HM43239) monotherapy in subjects with relapsed or treatment-refractory acute myeloid
leukemia (AML). This study will also evaluate the safety, tolerability, and PK parameters of
tuspetinib (HM43239) in combination with venetoclax when administered in patients with R/R
AML

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.